This might explain the negative findings from a recent clinical study reporting that HER2 overexpression does not seem to predispose to locoregional recurrence for breast cancer patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy and radiotherapy [39]. The gene discussed is ERBB2; the disease is breast carcinoma.